Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin with amphotericin B deoxycholate for the primary treatment of invasive candidiasis. METHODS: We enrolled patients who had clinical evidence of infection and a positive culture for candida species from blood or another site. Patients were stratified according to the severity of disease, as indicated by the Acute Physiology and Chronic Health Evaluation (APACHE II) score, and the presence or absence of neutropenia and were randomly assigned to receive either caspofungin or amphotericin B. The study was designed to compare the efficacy of caspofungin with that of amphotericin B in patients with invasive candidiasis and in a subgroup with candidemia. RESULTS: Of the 239 patients enrolled, 224 were included in the modified intention-to-treat analysis. Base-line characteristics, including the percentage of patients with neutropenia and the mean APACHE II score, were similar in the two treatment groups. A modified intention-to-treat analysis showed that the efficacy of caspofungin was similar to that of amphotericin B, with successful outcomes in 73.4 percent of the patients treated with caspofungin and in 61.7 percent of those treated with amphotericin B (difference after adjustment for APACHE II score and neutropenic status, 12.7 percentage points; 95.6 percent confidence interval, -0.7 to 26.0). An analysis of patients who met prespecified criteria for evaluation showed that caspofungin was superior, with a favorable response in 80.7 percent of patients, as compared with 64.9 percent of those who received amphotericin B (difference, 15.4 percentage points; 95.6 percent confidence interval, 1.1 to 29.7). Caspofungin was as effective as amphotericin B in patients who had candidemia, with a favorable response in 71.7 percent and 62.8 percent of patients, respectively (difference, 10.0 percentage points; 95.0 percent confidence interval, -4.5 to 24.5). There were significantly fewer drug-related adverse events in the caspofungin group than in the amphotericin B group. CONCLUSIONS: Caspofungin is at least as effective as amphotericin B for the treatment of invasive candidiasis and, more specifically, candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For invasive candidiasis, echinocandins were a great development that lowered the mortality associated with these infections, with low toxicity and few interactions with other medication (Mora-Duarte et al., 2002; Pappas et al., 2016).”
From Fungal Cell Wall: Emerging Antifungals and Drug Resistance. (2019) · cites this paper as Mora-Duarte et al., 2002
In the citing paper
“Although morbidity and mortality associated with invasive Candida infections remains high, only four major classes of antifungal agents are currently approved for systemic therapy.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“The echinocandins, as first-line therapy for most Candida infections, have an overall failure rate of 25–30% in invasive candidiasis in clinical trials, and notably have little activity within the urinary tract.18,133,140–144”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [143]
In the citing paper
“Safety and tolerability were similar between the two groups and were consistent with the reported safety profile of echinocandin class drugs. 22-26”
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Pfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Bartizal, K., Gill, C. J., Abruzzo, G. K., Flattery, A. M., Kong, L., Scott, P. M., Smith, J. G., Leighton, C. E., Bouffard, A., Dropinski, J. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2326 · Cited by 311
Villanueva, A., Arathoon, E. G., Gotuzzo, E., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/323401 · Cited by 308
Self-citationVillanueva, A., Gotuzzo, E., Arathoon, E. G., Noriega, L. M., Kartsonis, N. A., Lupinacci, R. J., Smietana, J. M., DiNubile, M. J., & Sable, C. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01191-9 · Cited by 292
Self-citation
Research works printed but not linked: 4
- Bodey GP. Hematogenous and major organ candidiasis. In: Bodey GP, ed. Candidiasis: pathogenesis, diagnosis, and treatment. 2nd ed. New York: Raven Press, 1992:279-329.
- Yamamura DL, 1999, CMAJ, 160, 493
- Bachman SP, Pera S, Kirkpatrick WR, Patterson TF, Lopez-Ribot JL. In vitro activity of Cancidas (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000. Washington, D.C.: American Society for Microbiology, 2000:352. abstract.
- Nucci M, Santos LM, Ferradosa AS, Colombo AL. Epidemiology of candidemia due to C. parapsilosis in tertiary care hospitals in Brazil. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001. Washington, D.C.: American Society for Microbiology, 2001:393. abstract.
Cited by
Items 501–600 of 1,000
Cornet, M., Gaillardin, C., & Richard, M. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00391-06 · Cited by 30
Infectious Complications in Renal Transplant Recipients
Parasuraman, R., Yee, J., Karthikeyan, V., & Busto, R. D. (2006) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2006.04.008 · Cited by 32
New agents for invasive mycoses in children
Antachopoulos, C., & Walsh, T. J. (2005) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000150630.83442.e1 · Cited by 33
Intensive care triage—The hardest rationing decision of them all*
Levin, P. D., & Sprung, C. L. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000208355.77757.9c · Cited by 31
García‐Effrón, G., Park, S., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01350-10 · Cited by 34
Mónge-Nájera, J., & Ho, Y. (2012) · Revista de Biología Tropical · doi:10.15517/rbt.v60i4.2158 · Cited by 30
Egger, M., Bellmann, R., Krause, R., Boyer, J., Jakšić, D., & Hoenigl, M. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s372546 · Cited by 31
Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait
Asadzadeh, M., Al‐Sweih, N., Ahmad, S., & Khan, Z. U. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01492.x · Cited by 34
Kang, W., Song, G., Lee, S., Suh, K., Lee, K., Yi, N., Joh, J., Kwon, C. H. D., Kim, J. M., Choi, D. L., et al. (2019) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-019-04241-w · Cited by 33
Recent advances in antifungal pharmacotherapy for invasive fungal infections
Gallagher, J. C., MacDougall, C., Ashley, E. S. D., & Perfect, J. R. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.2.253 · Cited by 36
Self-citationEffects of Amphotericin B and Caspofungin on Histamine Expression
Cleary, J. D., Schwartz, M. S., Rogers, P. D., de Mestral, J., & Chapman, S. W. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.8.966.32875 · Cited by 30
Berg, T., Aehling, N., Bruns, T., Welker, M., Weismüller, T. J., Trebicka, J., Tacke, F., Strnad, P., Sterneck, M. R., Settmacher, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2255-7246 · Cited by 32
Hope, W. W., Natarajan, P., & Goodwin, L. C. (2013) · Clinical Medicine · doi:10.7861/clinmedicine.13-5-507 · Cited by 38
Management of Invasive Candidiasis in the Intensive Care Unit
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Drugs · doi:10.2165/10898550-000000000-00000 · Cited by 30
Essentials in Candida bloodstream infection
Mellinghoff, S. C., Cornely, O. A., & Jung, N. (2018) · Infection · doi:10.1007/s15010-018-1218-1 · Cited by 32
Jensen, U. S., Knudsen, J. D., Østergaard, C., Gradel, K. O., Møller, J. K., & Schønheyder, H. C. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.12.007 · Cited by 29
Neoh, C. F., Slavin, M. A., Chen, S. C. ‐., Stewart, K., & Kong, D. C. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.08.010 · Cited by 32
Infections in Allogeneic Stem Cell Transplantation
Pereira, M. R., Pouch, S. M., & Scully, B. E. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_11 · Cited by 45
Demir, K. K., Butler‐Laporte, G., Corpo, O. D., Ekmekjian, T., Sheppard, D. C., Lee, T. C., & Cheng, M. P. (2021) · Mycoses · doi:10.1111/myc.13290 · Cited by 33
Qi, Z., Kang, Q., Jiang, C., Han, M., & Bai, L. (2015) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-015-6635-9 · Cited by 28
Systemic Antifungal Agents: An Update of Established and New Therapies
Loo, D. S. (2006) · Advances in Dermatology · doi:10.1016/j.yadr.2006.07.001 · Cited by 28
Falagas, M. E., Ntziora, F., Betsi, G. I., & Samonis, G. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.09.018 · Cited by 31
The pharmacology and clinical use of caspofungin
Hope, W. W., Shoham, S., & Walsh, T. J. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.263 · Cited by 32
Contemporary Strategies in the Prevention and Management of Fungal Infections
Koehler, P. A., & Cornely, O. A. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.003 · Cited by 28
Caspofungin versus amphotericin B for candidemia: A pharmacoeconomic analysis
Wingard, J. R., Wood, C. A., Sullivan, E. A., Berger, M. L., Gerth, W. C., & Mansley, E. C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.023 · Cited by 28
Endocarditis and Intravascular Infections
Fowler, V. G., Scheld, W. M., & Bayer, A. S. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00077-1 · Cited by 38
Leather, H. L., & Wingard, J. R. (2006) · Blood Reviews · doi:10.1016/j.blre.2006.03.001 · Cited by 33
Antifungal treatment strategies and their impact on resistance development in clinical settings
van Rhijn, N., & White, P. L. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf382 · Cited by 33
Keane, S., Geoghegan, P., Póvoa, P. M. S. R., Nseir, S., Rodríguez, A. H., & Martín‐Loeches, I. (2018) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2018.1528872 · Cited by 31
Neonatal liver abscesses due to Candida infection effectively treated with caspofungin
Filippi, L., Poggi, C., Gozzini, E., Meleleo, R., Mirabile, L., & Fiorini, P. (2009) · Acta Paediatrica · doi:10.1111/j.1651-2227.2009.01225.x · Cited by 30
Eggimann, P., Calandra, T., Flückiger, U. M., Billé, J., Garbino, J., Glauser, M., Marchetti, O., Ruef, C., Täuber, M. G., Pittet, D., et al. (2005) · Intensive Care Medicine · doi:10.1007/s00134-005-2809-8 · Cited by 32
Ngai, A. L., Bourque, M. R., Lupinacci, R. J., Strohmaier, K. M., & Kartsonis, N. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.07.008 · Cited by 27
Self-citationInvasive candidiasis and candidaemia in neonates and children: update on current guidelines
Tragiannidis, A., Tsoulas, C., & Groll, A. H. (2014) · Mycoses · doi:10.1111/myc.12268 · Cited by 40
Pharmacotherapy of yeast infections
Gómez‐López, A., Zaragoza, Ó., Rodríguez-Tudela, J. L., & Cuenca‐Estrella, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.16.2801 · Cited by 36
Candidemia in the in-patient setting: treatment options and economics
Gagne, J. J., & Goldfarb, N. I. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1643 · Cited by 28
Kullberg, B. J., Vasquez, J., Mootsikapun, P., Nucci, M., Paiva, J.-A., Garbino, J., Yan, J. L., Aram, J. A., Capparella, M. R., Conte, U., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx116 · Cited by 27
Coping with Candida Infections
Evans, S. E. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200907-075al · Cited by 32
Brzankalski, G. E., Najvar, L. K., Wiederhold, N. P., Bocanegra, R. A., Fothergill, A. W., Rinaldi, M. G., Pattterson, T. F., & Graybill, J. R. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn304 · Cited by 29
Pauw, B. E. D., & Patterson, T. F. (2005) · Clinical Infectious Diseases · doi:10.1086/430919 · Cited by 27
Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient
Nichols, W. G. (2003) · Journal of Intensive Care Medicine · doi:10.1177/0885066603258009 · Cited by 30
Gastrointestinal infections in immunocompromised hosts
Forrest, G. N. (2003) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200401000-00005 · Cited by 27
Newer antifungal therapy for emerging fungal pathogens
Steinbach, W. J., & Perfect, J. R. (2003) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(03)90037-3 · Cited by 27
Self-citationEchinocandins: Addressing outstanding questions surrounding treatment of invasive fungal infections
Holt, S. L., & Drew, R. H. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100456 · Cited by 26
Fungal infections of the skin and nail: new treatment options
Eldridge, M., Chambers, C. J., Sharon, V. R., & Thompson, G. R. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.960849 · Cited by 28
Clinical Pharmacology of Anti-Infective Drugs
Wade, K. C., & Benjamin, D. K. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6400-8.00037-7 · Cited by 32
Tsekoura, M., Ioannidou, M., Pana, Z. D., Haidich, A., Antachopoulos, C., Iosifidis, Ε., Kolios, G. C., & Roilides, E. (2018) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002032 · Cited by 30
Evaluation of size-based distribution of drug and excipient in amphotericin B liposomal formulation
Haute, D. V., Jiang, W., & Mudalige, T. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118603 · Cited by 26
Anidulafungin in the treatment of invasive fungal infections
Gumbo, T. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s882 · Cited by 27
Newer antifungal agents for invasive fungal infections in patients with haematological malignancy
Rogers, T. R., & Frost, S. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07412.x · Cited by 29
Maschmeyer, G., & Glasmacher, A. (2005) · Mycoses · doi:10.1111/j.1439-0507.2005.01131.x · Cited by 27
Meletiadis, J., Chanock, S. J., & Walsh, T. J. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.561 · Cited by 27
Suitability of Caspofungin for Aerosol Delivery
Wong‐Beringer, A., Lambros, M. P., Beringer, P. M., & Johnson, D. L. (2005) · CHEST Journal · doi:10.1378/chest.128.5.3711 · Cited by 26
Vigouroux, S., Morin, O., Moreau, P., Harousseau, J., & Milpied, N. J. (2006) · PubMed · Cited by 31
The Evolving Role of Antifungal Susceptibility Testing
Eschenauer, G. A., & Carver, P. L. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1233 · Cited by 26
Endotipsitis: A case report with a literature review on an emerging prosthetic related infection
Navaratnam, A. M. D., Grant, M., & Banach, D. B. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i4.710 · Cited by 25
Grossi, P., Gasperina, D. D., Barchiesi, F., Biancofiore, G., Carafiello, G., GASPERI, A. D., Sganga, G., Menichetti, F., Montagna, M. T., Pea, F., et al. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.06.020 · Cited by 26
Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions
Johnson, M. D., Kleinberg, M. E., Danziger, L. H., & Ostrosky-Zeichner, L. L. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.15.2617 · Cited by 25
Management ofCandidainfections in the adult intensive care unit
Cruciani, M., & Serpelloni, G. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.2.175 · Cited by 33
Priebe‐Richter, C., Ivanyi, P., Buer, J., Länger, F. P., Lotz, J., Hertenstein, B., Ganser, A., & Franzke, A. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00478.x · Cited by 25
Pasqualotto, A. C., & Denning, D. W. (2005) · European Oncology & Haematology · doi:10.17925/eoh.2005.0.0.1p · Cited by 32
Vázquez, J. A., & Sobel, J. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_11 · Cited by 37
Gavaldà, J., & Ruíz-Camps, I. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72995-4 · Cited by 34
Lichtenstern, C., Schmidt, J., Knaebel, H., Martin, E., Büchler, M. W., & Weigand, M. A. (2007) · Digestive Surgery · doi:10.1159/000099009 · Cited by 28
Schroeder, J. A., Wilson, C. M., & Pappas, P. G. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.11.007 · Cited by 31
Falcone, M., Tiseo, G., Gutiérrez‐Gutiérrez, B., Raponi, G., Carfagna, P., Rosin, C., Luzzati, R., Rose, D. D., Andreoni, M., Farcomeni, A., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz251 · Cited by 24
Cornely, O. A., Marty, F. M., Stucker, F., Pappas, P. G., & Ullmann, A. J. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02045.x · Cited by 26
The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia
Sobel, J. D. (2007) · Current Fungal Infection Reports · doi:10.1007/s12281-007-0007-6 · Cited by 26
Épidémiologie des candidémies : étude observationnelle prospective d’un an dans l’Ouest de la France
Talarmin, J. P., Boutoille, D., Tattevin, P., Dargère, S., Weinbreck, P., Ansart, S., Chennebault, J. M., Hutin, P., Leautez-Nainville, S., Gay‐Andrieu, F., et al. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.02.008 · Cited by 30
Walraven, C. J., Bernardo, S. M., Wiederhold, N. P., & Lee, S. A. (2014) · Medical Mycology · doi:10.1093/mmy/myt007 · Cited by 23
Invasive candidiasis; a review article
Zarrin, M., & Mahmoudabadi, A. Z. (2009) · Jundishapur Journal of Microbiology · Cited by 33
Schelenz, S., & Ross, C. N. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-126 · Cited by 25
Invasive candidiasis in the ICU: evidence based and on the edge of evidence
Hollenbach, E. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01571.x · Cited by 25
Clinical Pharmacokinetic Monitoring of Itraconazole Is Warranted in Only a Subset of Patients
Buchkowsky, S. S., Partovi, N., & Ensom, M. H. H. (2005) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000150135.22645.ea · Cited by 25
Combination antifungals: an update
Segal, B. H., & Steinbach, W. J. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.883 · Cited by 27
Rochat, B., Bolay, S., Pascual, A., Calandra, T., & Marchetti, O. (2007) · Journal of Mass Spectrometry · doi:10.1002/jms.1171 · Cited by 24
Candidainfections in the intensive care unit: epidemiology, risk factors and therapeutic strategies
Bassetti, M., Righi, E., Tumbarello, M., Biagio, A. D., Rosso, R., & Viscoli, C. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.5.875 · Cited by 26
Candidemia complicated by endophthalmitis: a prospective analysis
Kannangara, S., Shindler, D., Kunimoto, D. Y., Sell, B., & DeSimone, J. A. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0372-7 · Cited by 25
Abuhammour, W., & Habte‐Gabr, E. (2004) · The Indian Journal of Pediatrics · doi:10.1007/bf02724279 · Cited by 25
Darouiche, R. O. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.013 · Cited by 23
Sganga, G., Wang, M., Capparella, M. R., Tawadrous, M., Yan, J. L., Aram, J. A., & Montravers, P. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03617-9 · Cited by 25
Identification of Inhibitors of Fungal Fatty Acid Biosynthesis
DeJarnette, C. A., Meyer, C. J., Jenner, A. R., Butts, A., Peters, T. L., Cheramie, M. N., Phelps, G. A., Vita, N. A., Loudon, V. C., Lee, R. E., Jr., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00404 · Cited by 25
Domingos, E. L., Vilhena, R. D. O., dos Santos, J. M. M. F., Fachi, M. M., Böger, B., Adam, L. M., Tonin, F. S., & Pontarolo, R. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106614 · Cited by 23
Current aspects of invasive candidiasis and aspergillosis in adult intensive care patients
Glöckner, A., & Karthaus, M. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01885.x · Cited by 25
Genetically recombinant antibodies: new therapeutics against candidiasis
Burnie, J., & Matthews, R. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.2.233 · Cited by 28
Treatment of critically ill patients with candidemia
Mensa, J., Pitart, C., & Marco, F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70007-4 · Cited by 26
Shorr, A. F., Wu, C., & Kothari, S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq446 · Cited by 24
The use of caspofungin in HIV-infected individuals
Waters, L. J., & Nelson, M. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.899 · Cited by 23
Is there a role for polyenes in treating invasive mycoses?
Cornely, O. A., Vehreschild, J. J., & Ullmann, A. J. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328010851d · Cited by 24
Riddell, J., & Kauffman, C. A. (2008) · Cancer · doi:10.1002/cncr.23465 · Cited by 23
Recomendaciones para el manejo de la candidemia en niños en América Latina
Santolaya, M. E., Telles, F. D. Q., Matute, T. A., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.011 · Cited by 24
Self-citationMartino, R., Cortés, M., Subirá, M., Parody, R., Moreno, E., & Sierra, J. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500205486 · Cited by 23
Efficacy and Safety of Caspofungin in Solid Organ Transplant Recipients
Petrovic, J., Ngai, A., Bradshaw, S. K., Williams‐Diaz, A., Taylor, A., Sable, C. A., Vuocolo, S. C., & Kartsonis, N. A. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.10.003 · Cited by 23
Self-citationLumbreras, C., Lizasoaín, M., & Aguado, J. M. (2003) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(03)72964-4 · Cited by 45
Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy
Lass‐Flörl, C. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.128 · Cited by 26
Specific infectious complications after stem cell transplantation
Hebart, H. F., & Einsele, H. (2004) · Supportive Care in Cancer · doi:10.1007/s00520-003-0511-3 · Cited by 27
Trend Reversal in the Frequency of Mycoses in Hematological Neoplasias
Donhuijsen, K., Petersen, P., & Schmid, K. W. (2008) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2008.0501 · Cited by 26
Horn, D., Neofytos, D., Fishman, J. A., Steinbach, W. J., Anaissie, E. J., Marr, K. A., Pfaller, M. A., & Olyaei, A. J. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0383-4 · Cited by 25
Update in Infectious Diseases in Liver Transplant Recipients
Huprikar, S. S. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.04.006 · Cited by 22
Clinical pharmacology of antifungal agents in pediatric patients
Chiou, C. C., Walsh, T. J., & Groll, A. H. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2465 · Cited by 25
In vitro activity of five antifungal drugs against Candida albicans isolates in Sari, Iran
Afsarian, S. M. H. (2016) · Current Medical Mycology · doi:10.18869/acadpub.cmm.2.2.8 · Cited by 25
Metadata
- Authors
- Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J.
- Affiliations
- Costa Rican Department of Social Security (CR)
- University of Rochester (US)
- McMaster University (CA)
- Universidade Federal de São Paulo (BR)
- Clinica Santa Maria (CL)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-12-19
- Volume
- 347
- Issue
- 25
- Pages
- 2020-2029
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003661565
- Cited by
- 1,380
- References
- 31
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 17 · 2023: 14 · 2022: 18 · 2021: 30 · 2020: 28 · 2019: 30 · 2018: 29 · 2017: 44 · 2016: 30 · 2015: 50 · 2014: 44 · 2013: 53 · 2012: 62
- FWCI
- 56.95
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- caspofungin, amphotericin B deoxycholate, invasive candidiasis, candidemia, echinocandins, antifungal therapy, treatment efficacy, drug-related adverse events, neutropenia, APACHE II score, Candida species, randomized trial comparison, length of hospital stay, cost-effectiveness
- MeSH terms
- Caspofungin, Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Anti-Bacterial Agents, Antifungal Agents, Candida, Candidiasis, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Peptides, Peptides, Cyclic, Recurrence, Fungemia, APACHE, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.